CURRENT
ISSUE
1627

The investigational monoclonal antibody sotrovimab (VIR-7831; GSK/Vir Biotechnology) has been granted an FDA Emergency Use Authorization (EUA) for treatment of mild to moderate COVID-19 in patients ≥12 years old who weigh ≥40 kg and are at high risk of progressing to severe disease, including hospitalization and death.1 Two other monoclonal antibody regimens are authorized for the same indication: casirivimab (REGN10933) and imdevimab (REGN10987) administered together,2 and bamlanivimab (LY-CoV555) and etesevimab (LYCoV016) administered together.3 The FDA revoked its EUA for bamlanivimab alone in April 2021...  Continue reading

More from Issue 1627
Previous Issue: 1626      June 14, 2021
Coming Soon
Insect Repellents
Aducanumab (Aduhelm) for Alzheimer's Disease
Semaglutide (Wegovy) for Weight Loss
Sunscreens
Search
Donate
Subscribe
Conversation
Follow us   Twitter LinkedIn YouTube Blog RSS   Email Alerts
FROM
ISSUE
1627

The FDA has approved viloxazine extended-release capsules (Qelbree – Supernus) for treatment of attention-deficit/hyperactivity disorder (ADHD) in children 6-17 years old. Viloxazine is the second selective norepinephrine reuptake inhibitor to be approved in the US for treatment of ADHD; atomoxetine (Strattera, and generics) was approved in 2002.

STANDARD TREATMENT — Stimulants such as amphetamines and ... Continue reading

 Tweets